CKD

Metabolic Health

Beyond Weight Loss: What the Latest GLP-1 Evidence Says About Liver, Kidney, Heart, and Cost

Fresh 2025 reviews map semaglutide's reach into fatty liver disease, cardiovascular risk, kidney protection — and the economics of treating obesity at scale. The signals are real, but the picture is still filling in.

Peptides

GLP-1s Move Beyond Weight Loss: Parkinson's, Kidneys, Eyes, and the Brain

A phase 3 Parkinson's trial, a kidney meta-analysis, an ocular cohort and new mechanistic work suggest the GLP-1 class is becoming a multi-system intervention — with important caveats.